The phase II open label single-center dose escalation study (n=14) assessed the safety and efficacy of Xiaflex in patients with lipoma, divided into four dose cohorts. The data from the trial showed ...

Investors eagerly wait for updates on the pipelines of biopharma/biotech companies. Such updates including label expansions of marketed products help them to decide whether or not to invest in a ...

MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ -- Endo, Inc. ("Endo") (OTCQX: NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his ...

MALVERN, Pa., Nov. 20, 2024 /PRNewswire/ -- Endo, Inc. (NDOI) announced today that John Elway will share an update about his Dupuytren's contracture patient journey, including his treatment with ...

Endo International plc's (NASDAQ:ENDP) subsidiary Endo Pharmaceuticals Inc. announced positive data from a phase II trial which evaluated the safety and efficacy of Xiaflex (collagenase clostridium ...

Endo International plc's ENDP subsidiary Endo Pharmaceuticals Inc. announced positive data from a phase II trial which evaluated the safety and efficacy of Xiaflex (collagenase clostridium ...

XIAFLEX has been granted orphan status in the U.S. by the FDA for DC and PD. About Auxilium Auxilium Pharmaceuticals, Inc. is a specialty biopharmaceutical company with a focus on developing and ...

Endo International plcENDP announced that it has initiated a phase IIb study on Xiaflex (collagenase clostridium histolyticum) for the treatment of patients with cellulite, also known as edematous ...

We recently reiterated our Neutral recommendation on Auxilium Pharmaceuticals, Inc. (AUXL) which carries a Zacks #3 Rank (short-term ‘Hold’ rating). Auxilium Pharma’s lead product Testim, a 1% ...

XIAFLEX is a biologic approved in the U.S., EU, Canada and Australia for the treatment of adult DC patients with a palpable cord and, in the U.S. for the treatment of adult men with Peyronie's disease ...

LYNBROOK, N.Y., Nov. 21, 2014 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX ® ...